Luke, Jason J http://orcid.org/0000-0002-1182-4908
Barlesi, Fabrice
Chung, Ki
Tolcher, Anthony W
Kelly, Karen http://orcid.org/0000-0002-2235-6636
Hollebecque, Antoine
Le Tourneau, Christophe
Subbiah, Vivek
Tsai, Frank
Kao, Steven
Cassier, Philippe A
Khasraw, Mustafa
Kindler, Hedy L
Fang, Hua
Fan, Frances
Allaire, Kathryn
Patel, Maulik
Ye, Shiming
Chao, Debra T
Henner, William R
Hayflick, Joel S
McDevitt, Michael A
Fong, Lawrence
Clinical trials referenced in this document:
Documents that mention this clinical trial
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
https://doi.org/10.1136/esmoopen-2019-000510
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2020-002015
Documents that mention this clinical trial
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
https://doi.org/10.1136/jitc-2021-002459
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2020-002015
259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC
https://doi.org/10.1136/jitc-2020-sitc2020.0259
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events
https://doi.org/10.1136/jitc-2023-006814
Funding for this research was provided by:
AbbVie